TY - JOUR
T1 - Comparative loss of activity of recombinant secretory leukoprotease inhibitor and α 1-protease inhibitor caused by different forms of oxidative stress
AU - Vogelmeier, C.
AU - Biedermann, T.
AU - Maier, K.
AU - Mazur, G.
AU - Behr, J.
AU - Krombach, F.
AU - Buhl, R.
PY - 1997/9
Y1 - 1997/9
N2 - Secretory leukoprotease inhibitor (SLPI) and α 1-protease inhibitor α 1-PI) are powerful antiproteases currently under investigation for their potential to protect the lung from neutrophil elastase (NE). The aim of this study was to determine whether the recombinant form of SLPI (rSLPI) and α 1-PI show different grades of loss of inhibitory activity when exposed to reactive oxygen metabolites. We incubated rSLPI and α 1-PI with N-chlorosuccinimide (NCS), chloramines, activated polymorphonuclear leucocytes (PMNs) and activated alveolar macrophages (AMs). Under all conditions evaluated, both antiproteases were partially inactivated. The resulting anti-NE activity of rSLPI was not significantly different from that of α 1-PI after exposure to NCS (p > 0.5), chloramines (p > 0.6), activated PMNs (p > 0.07) and activated AMs (p > 0.9). In conclusion, recombinant secretory leukoprotease inhibitor and α 1-protease inhibitor lose antineutrophil elastase activity to a similar extent when exposed to conditions that may be present in inflammatory lung disorders.
AB - Secretory leukoprotease inhibitor (SLPI) and α 1-protease inhibitor α 1-PI) are powerful antiproteases currently under investigation for their potential to protect the lung from neutrophil elastase (NE). The aim of this study was to determine whether the recombinant form of SLPI (rSLPI) and α 1-PI show different grades of loss of inhibitory activity when exposed to reactive oxygen metabolites. We incubated rSLPI and α 1-PI with N-chlorosuccinimide (NCS), chloramines, activated polymorphonuclear leucocytes (PMNs) and activated alveolar macrophages (AMs). Under all conditions evaluated, both antiproteases were partially inactivated. The resulting anti-NE activity of rSLPI was not significantly different from that of α 1-PI after exposure to NCS (p > 0.5), chloramines (p > 0.6), activated PMNs (p > 0.07) and activated AMs (p > 0.9). In conclusion, recombinant secretory leukoprotease inhibitor and α 1-protease inhibitor lose antineutrophil elastase activity to a similar extent when exposed to conditions that may be present in inflammatory lung disorders.
KW - Inactivation
KW - Reactive oxygen metabolites
KW - Secretory leukoprotease inhibitor
KW - Therapy
KW - α -protease inhibitor
UR - http://www.scopus.com/inward/record.url?scp=0030987526&partnerID=8YFLogxK
U2 - 10.1183/09031936.97.10092114
DO - 10.1183/09031936.97.10092114
M3 - Article
C2 - 9311513
AN - SCOPUS:0030987526
SN - 0903-1936
VL - 10
SP - 2114
EP - 2119
JO - European Respiratory Journal
JF - European Respiratory Journal
IS - 9
ER -